Company
ChinaBoehringer Ingelheim Biopharmaceuticals (China) Ltd., China – FDA Inspections
Inspection records and compliance data for Boehringer Ingelheim Biopharmaceuticals (China) Ltd.. 2 FDA inspections on record, 2 Form 483s, last inspected July 24, 2026.
Company Profile
This profile covers Boehringer Ingelheim Biopharmaceuticals (China) Ltd. based in China.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 2
- Form 483s
- 2
- Warning letters
- 0
First inspected June 9, 2023. Last inspected July 24, 2026.
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| July 24, 2026 | Not classified | Human Drugs | 1330776 |
| June 9, 2023 | Not classified | Human Drugs | 1218076 |
FDA documents
Form 483s (1)
People (2)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Sun Pharmaceutical Medicare Limited
Wacker Biotech B.V.
Regeneron Pharmaceuticals Inc
Abbvie Biotechnology Ltd.
Chugai Pharma Manufacturing Co. Ltd.
BSP Pharmaceuticals SpA
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Avista Pharma Solutions, Inc. dba Cambrex
Alexion Pharma International Operations Unlimited Co.
Janssen Biotech, Inc.
Company Information
Name
Boehringer Ingelheim Biopharmaceuticals (China) Ltd.
FEI Number
3015009021
Address
China
Country
China
ID: be450a8b-4f71-4f06-96b3-908a2ed1b580